Verdenelli M C, Coman M M, Cecchini C, Silvi S, Orpianesi C, Cresci A
School of Biosciences and Biotechnologies, University of Camerino, Camerino, Italy; Synbiotec S.r.l., Spin-off of UNICAM, Camerino, Italy.
J Appl Microbiol. 2014 May;116(5):1297-307. doi: 10.1111/jam.12459. Epub 2014 Feb 19.
To test different Lactobacillus strains for their antipathogenic activity towards Candida strains and their adhesion properties for the preparation of vaginal ovules and douches to be used in vaginal candidiasis prevention.
Five strains of lactobacilli were tested for their antimicrobial potential against different clinically isolated Candida strains. They were also screened for their ability to produce hydrogen peroxide and to coaggregate with pathogens. Adhesion properties of the five different Lactobacillus strains to HeLa cells and the presence of arcA gene were also assessed. The in vitro experiments demonstrated that all the five Lactobacillus strains tested possessed inhibitory action against the Candida strains using the radial streak method, but the effect is strain dependent. The same situation arises with regard to the ability of coaggregation that is present in all the strains into different degrees. Only Lactobacillus rhamnosus IMC 501(®) and Lactobacillus paracasei IMC 502(®) were able to produce H2O2 and none of the strains possess arcA gene. The most adherent strains to HeLa cells were Lact. rhamnosus IMC 501(®), Lact. paracasei IMC 502(®) and also their combination SYNBIO(®). This latter was selected for the preparation of ovules and douches using different matrix. Witepsol(®) ovules have proved the best formulation in terms of probiotic viability.
Lactobacillus rhamnosus IMC 501(®), Lact. paracasei IMC 502(®) and SYNBIO(®) were able to produce H2O2, to coaggregate and to exert antimicrobial activity against pathogenic Candida strains and to strongly adhere to HeLa cells. All these properties together with those technological make these strains good candidates for the realization of formulations suitable for vaginal health.
To develop new vaginal formulations taking into account the impact of probiotic strains on pathogens as well as the technological properties of the strains to validate their effectiveness in human health.
测试不同的乳酸杆菌菌株对念珠菌菌株的抗致病活性及其黏附特性，以制备用于预防阴道念珠菌病的阴道栓剂和灌洗剂。
测试了五株乳酸杆菌对不同临床分离念珠菌菌株的抗菌潜力。还筛选了它们产生过氧化氢以及与病原体共聚集的能力。评估了五种不同乳酸杆菌菌株对HeLa细胞的黏附特性以及arcA基因的存在情况。体外实验表明，使用径向划线法测试的所有五株乳酸杆菌菌株对念珠菌菌株均具有抑制作用，但效果因菌株而异。所有菌株的共聚集能力也存在不同程度的差异。只有鼠李糖乳杆菌IMC 501(®)和副干酪乳杆菌IMC 502(®)能够产生H2O2，且所有菌株均不具有arcA基因。对HeLa细胞黏附性最强的菌株是鼠李糖乳杆菌IMC 501(®)、副干酪乳杆菌IMC 502(®)及其组合SYNBIO(®)。选择后者使用不同基质制备栓剂和灌洗剂。就益生菌活力而言，Witepsol(®)栓剂已证明是最佳配方。
鼠李糖乳杆菌IMC 501(®)、副干酪乳杆菌IMC 502(®)和SYNBIO(®)能够产生H2O2、共聚集并对致病性念珠菌菌株发挥抗菌活性，且能强烈黏附于HeLa细胞。所有这些特性以及相关技术特性使这些菌株成为制备适合阴道健康制剂的良好候选菌株。
考虑益生菌菌株对病原体的影响以及菌株的技术特性，开发新的阴道制剂，以验证其在人类健康中的有效性。
